What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Ian Judson mainly focuses on Internal medicine, Surgery, Sarcoma, Chemotherapy and Oncology.
The various areas that Ian Judson examines in his Internal medicine study include Gastroenterology and Pathology.
The concepts of his Gastroenterology study are interwoven with issues in Pharmacokinetics, Neutropenia, Toxicity, Asymptomatic and Rash.
His work deals with themes such as Cancer, Radiation therapy and Imatinib mesylate, which intersect with Sarcoma.
His biological study spans a wide range of topics, including Pharmacodynamics and Pharmacology.
His Oncology research is multidisciplinary, incorporating elements of Vincristine, Prospective cohort study and Liposarcoma.
His most cited work include:
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial (1974 citations)
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function. (1620 citations)
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial* (1359 citations)
What are the main themes of his work throughout his whole career to date?
Ian Judson mostly deals with Internal medicine, Surgery, Sarcoma, Oncology and Chemotherapy.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Soft tissue sarcoma.
His research in Sarcoma intersects with topics in Progression-free survival and Leiomyosarcoma.
His Oncology research includes themes of Progressive disease, Disease, Phases of clinical research, Randomized controlled trial and Placebo.
Ian Judson combines subjects such as Pharmacokinetics, Radiation therapy, Toxicity and Urology with his study of Chemotherapy.
His Cancer study integrates concerns from other disciplines, such as Cancer research and Pharmacology.
He most often published in these fields:
- Internal medicine (48.03%)
- Surgery (33.96%)
- Sarcoma (30.77%)
What were the highlights of his more recent work (between 2013-2021)?
- Internal medicine (48.03%)
- Sarcoma (30.77%)
- Oncology (29.27%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Internal medicine, Sarcoma, Oncology, Surgery and Soft tissue sarcoma.
His research integrates issues of Cancer, Clinical trial and GiST in his study of Sarcoma.
His Oncology research also works with subjects such as
- Bone Sarcoma, which have a strong connection to Retrospective analysis,
- Progressive disease together with Gastroenterology.
His work in Surgery is not limited to one particular discipline; it also encompasses Urology.
His Soft tissue sarcoma research is multidisciplinary, relying on both Physical therapy, Leiomyosarcoma and Doxorubicin.
His Chemotherapy study combines topics in areas such as Radiation therapy and Disease.
Between 2013 and 2021, his most popular works were:
- Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† (739 citations)
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial (531 citations)
- Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (297 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Surgery, Sarcoma, Internal medicine, Oncology and Ifosfamide.
His Sarcoma research includes elements of Radiation therapy, GiST and MEDLINE.
The GiST study combines topics in areas such as Clinical trial, Cohort study, Imatinib mesylate, Rectum and Pelvic exenteration.
His Internal medicine study combines topics from a wide range of disciplines, such as Soft tissue sarcoma and Gastroenterology.
The various areas that Ian Judson examines in his Oncology study include Chondrosarcoma, Cancer registry and Primitive neuroectodermal tumor.
His Ifosfamide research is multidisciplinary, relying on both Urology, Cyclophosphamide and Doxorubicin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
